



Technology for the Treatment of Neurodegenerative Diseases Targeting Alzheimer's Disease

Alzex Biomedical Group (ALZEX) is a private company that has entered into an agreement with a French Biotech Company, VFP THERAPIES.

ALZEX is a collaboration of researchers, scientists, and investors that have developed and patented precision therapeutics for the treatment of Alzheimer's Disease (AD) and other neurological diseases.

ALZEX currently holds a multiple family of patents, proof of concept has been done and preclinical trials are ongoing.

Our North American headquarters is located in Vancouver B.C with our subsidiary VFP THERAPIES laboratories located in France (Normandy).

Alzex has developed innovative drug candidates called the Bioprecursor.

VFP THERAPIES Innovative Concept of Bioprecursor

- ❖ Chemically masked form of a biological active molecule
- ❖ No recognition by the biological receptors
- ❖ Lipophilic small molecule crossing the Blood Brain Barrier (BBB)

Bioprecursor Activated inside the Brain: biological oxidative pathway

- ❖ Recognition by the biological receptors
- ❖ Induction of the targeted pharmacological effects
- ❖ Limitation of peripheral side-effects

Proof of Concept is achieved

- ❖ Successful design of new drugs for AD mimicking commercial ones
- ❖ Bioprecursor technology can be applied to other brain diseases